Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 194 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CD Clear all
Completed Phase 2 Interventional

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

NCT00672191
View directory record Official record
Conditions
HIV Infections
Interventions
AGS-004
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 20, 2026, 7:03 PM EDT
Active, not recruiting No phase listed Observational

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
Interventions
Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Recruiting Phase 2 Interventional

HB-adMSCs for the Treatment of Crohn's Disease

NCT07077746
View directory record Official record
Conditions
Crohn Disease (CD)
Interventions
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride
Drug
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Not applicable Interventional Results available

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

NCT05651542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Comprehensive Self-Management Intervention, Control
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

NCT00763503
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
CD 2027
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Hot Springs, Arizona • Austin, Texas • Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

NCT01925417
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 7:03 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

NCT00839007
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
CD-NP
Drug
Lead sponsor
Nile Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Torrance, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 20, 2026, 7:03 PM EDT
Completed No phase listed Observational

DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia

NCT01314365
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Scottsdale, Arizona • Berkeley, California • Encinitas, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 20, 2026, 7:03 PM EDT
Not listed No phase listed Observational

Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection in Synovial Fluid

NCT02868736
View directory record Official record
Conditions
Periprosthetic Joint Infection
Interventions
Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test
Device
Lead sponsor
CD Diagnostics
Industry
Eligibility
22 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 20, 2026, 7:03 PM EDT
Not listed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

NCT02605434
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 20, 2026, 7:03 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Crohn's Disease and Ulcerative Colitis Study

NCT01169207
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

NCT02793778
View directory record Official record
Conditions
Crohn's Disease
Interventions
CROWN, CROWN Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Dothan, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Intervention for Crohn's Disease Patient

NCT04213729
View directory record Official record
Conditions
Crohn Disease
Interventions
Diet Counseling, CD LFD, Dyadic Psychological Support (DPS)
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 20, 2026, 7:03 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Withdrawn Phase 2 Interventional

Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

NCT04339751
View directory record Official record
Conditions
Cushing's Disease
Interventions
Vorinostat
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 20, 2026, 7:03 PM EDT
Active, not recruiting No phase listed Observational

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 20, 2026, 7:03 PM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

NCT03011931
View directory record Official record
Conditions
Celiac Disease
Interventions
Simvastatin
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 20, 2026, 7:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

NCT00787527
View directory record Official record
Conditions
Lymphoma
Interventions
Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 20, 2026, 7:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

NCT07852273
View directory record Official record
Conditions
Inflamatory Bowel Disease, Crohn Disease (CD)
Interventions
Sucralose (non-nutritive sweetener)
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chagrin Falls, Ohio • Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Active, not recruiting No phase listed Observational

Response Assessment in SB CD

NCT03646708
View directory record Official record
Conditions
Small Bowel Crohn's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Not yet recruiting Not applicable Interventional

VR Therapies for IBD

NCT07590518
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn Disease (CD), Anxiety
Interventions
Distraction VR, VR/AI CBT
Device
Lead sponsor
Brennan Spiegel
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 7:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 20, 2026, 7:03 PM EDT